577 related articles for article (PubMed ID: 23421098)
21. [Cannabis and cannabinoids-easier access, hype and disappointment : What has been confirmed in therapy?].
Rasche T; Emmert D; Stieber C; Conrad R; Mücke M
Internist (Berl); 2019 Mar; 60(3):309-314. PubMed ID: 30680416
[TBL] [Abstract][Full Text] [Related]
22. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats.
Parker LA; Mechoulam R; Schlievert C
Neuroreport; 2002 Apr; 13(5):567-70. PubMed ID: 11973447
[TBL] [Abstract][Full Text] [Related]
23. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Russo EB
Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
[No Abstract] [Full Text] [Related]
24. Medical Use of Cannabinoids.
Fraguas-Sánchez AI; Torres-Suárez AI
Drugs; 2018 Nov; 78(16):1665-1703. PubMed ID: 30374797
[TBL] [Abstract][Full Text] [Related]
25. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.
Mechoulam R; Hanu L
Pain Res Manag; 2001; 6(2):67-73. PubMed ID: 11854768
[TBL] [Abstract][Full Text] [Related]
26. Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting.
Pergolizzi JV; Taylor R; LeQuang JA; Zampogna G; Raffa RB
Cancer Chemother Pharmacol; 2017 Mar; 79(3):467-477. PubMed ID: 28235999
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases.
Rodríguez Mesa XM; Moreno Vergara AF; Contreras Bolaños LA; Guevara Moriones N; Mejía Piñeros AL; Santander González SP
Cannabis Cannabinoid Res; 2021 Jun; 6(3):196-210. PubMed ID: 34030476
[No Abstract] [Full Text] [Related]
28. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.
Davis MP
Expert Opin Investig Drugs; 2008 Jan; 17(1):85-95. PubMed ID: 18095921
[TBL] [Abstract][Full Text] [Related]
29. Established and potential therapeutic applications of cannabinoids in oncology.
Walsh D; Nelson KA; Mahmoud FA
Support Care Cancer; 2003 Mar; 11(3):137-43. PubMed ID: 12618922
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoids and multiple sclerosis.
Pertwee RG
Pharmacol Ther; 2002 Aug; 95(2):165-74. PubMed ID: 12182963
[TBL] [Abstract][Full Text] [Related]
31. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses.
Breijyeh Z; Jubeh B; Bufo SA; Karaman R; Scrano L
Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33562446
[TBL] [Abstract][Full Text] [Related]
32. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic issues of marijuana and THC (tetrahydrocannabinol).
Ungerleider JT; Andrysiak T
Int J Addict; 1985 May; 20(5):691-9. PubMed ID: 2995262
[TBL] [Abstract][Full Text] [Related]
34. The cannabis paradox.
Ladouceur R
Can Fam Physician; 2018 Feb; 64(2):86. PubMed ID: 29449225
[No Abstract] [Full Text] [Related]
35. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
36. Cannabis and cannabinoids.
Med Lett Drugs Ther; 2019 Nov; 61(1585):179-182. PubMed ID: 31770357
[No Abstract] [Full Text] [Related]
37. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
Trebst C; Stangel M
Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
[TBL] [Abstract][Full Text] [Related]
38. Role of cannabis in digestive disorders.
Goyal H; Singla U; Gupta U; May E
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
[TBL] [Abstract][Full Text] [Related]
39. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
40. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
Podda G; Constantinescu CS
Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
